Syphilis Management Tool**

WHO TO TEST

Clinical indications:

- Consistent symptoms. e.g. genital, anal or oral ulcers (usually painless) or generalized maculopapular rash (typically including palms and soles)
- Sexual contacts
- Pregnant people at least three times during pregnancy



- > First trimester, 28-32 weeks and at delivery
 - > More frequent testing if ongoing risk.
 - > Monthly testing if new infection/treatment.
- People with new, multiple, or anonymous sexual partners (every 3 to 6 months)
- Anyone requesting testing
- Anyone with any new confirmed or suspected STI

Offer STBBI testing to all clients/ patients as part of routine care.

If you test for one, consider testing for all STBBIs

HOW TO TEST

Cadham Provincial Laboratory (CPL) requisition:

Always include:

Reason for testing (e.g. symptoms or treatment monitoring)

Collect:

Serology: 5-10 mL blood in a red-stoppered tube or a serum separator tube (red top with yellow cap). Draw sample prior to or on same day as treatment.

On CPL requisition:

- STBBI Panel (syphilis, HBsAq, HCV Ab and HIV 1/2 Ag/Ab Combo) or;
- Prenatal Panel (syphilis, HBsAg, and HIV 1/2 Ag/Ab Combo) – doesn't include HCV Ab or:
 - Syphilis Screen

Swabs: use a flocked swab in universal transport medium for ulcers, sores, moist skin lesions or newborn nasal discharge 🚣 . Keep refrigerated until sent to CPL.

• On CPL requisition, indicate site and test requested -"syphilis PCR" or "lesion panel".

Cerebral spinal fluid (CSF): ≥1 mL CSF in a sterile container. Keep refrigerated until sent to CPL.

. On CPL requisition, indicate site and test requested -"VDRL" and, if indicated "syphilis PCR".

If you are sending a swab for syphilis PCR or CSF for VDRL, also request blood for syphilis serology.

**Refer to Manitoba Health syphilis protocol for more details.


Manitoba Health Syphilis Protocol: www.gov.mb.ca/health/publichealth/cdc/protocol/syphilis.pdf Provider Report Form for STBBI and STI treatment (MHSU 6781) including contacts: www.gov.mb.ca/health/publichealth/ surveillance/docs/mhsu 6781.pdf

Manitoba Health STI Medication Order Form: www.qov.mb.ca/health/publichealth/cdc/protocol/form11.pdf

HOW TO INTERPRET SEROLOGY RESULTS

Treponemal Test Results – With No Previous History of Positive Syphilis

Serology (If patient previously tested positive, refer to "How to assess for reinfection" on page 2)



- Treponemal Tests:
 - > **CMIA** = *Treponema pallidum* Ab IqG + IqM
- > **TP-PA** = *Treponema pallidum* Ab; Aggl
- > **FTA-ABS** (CSF test) = *Treponema pallidum* Ab; CSF; ImF
- Non-Treponemal Tests (reported as non-reactive or reactive and a titre):
 - > **RPR** = Reagin Ab (Syphilis); RPR
 - > VDRL = Reagin Ab (Syphilis); VDRL

• For Public Health: Negative results will not appear in PHIMS, but can be found in eChart Manitoba. If RPR result is non-reactive but CMIA is positive, only a "final syphilis interpretation" will be reported.



HOW TO DETERMINE STAGING, TREATMENT AND CONTACTS Preferred treatment **Adequate Serologic** Trace back period **Clinical presentation** Stage (may include): and follow-up testing Response* for contacts 6 months: 4-fold drop Penicillin G Benzathine, 2.4 million units Primary Genital, anal or oral ulcerative lesions (usually painless), 3 months regional lymphadenopathy. The initial ulcer typically (MU) IM X 1 (in pregnancy give weekly X 2) 12 months: 8-fold drop heals spontaneously after a few weeks. Test 3, 6, 12 months after treatment 24 months: 16-fold drop Infectious Generalized maculopapular nonpruritic rash (typically Penicillin G Benzathine, 2.4 MU IM X 1 6 months: 8-fold drop Secondary 6 months on palms and soles), condyloma lata, other rash types, (in pregnancy give weekly X 2) 12 months: 16-fold drop fever, generalized lymphadenopathy, alopecia Test 3, 6, 12 months after treatment Early latent Asymptomatic, only detected with serologic Penicillin G Benzathine, 2.4 MU IM X 1# 12 months: 4-fold drop 1 year (< 1 year since screening. Distinction of early vs. late latent is based (in pregnancy give weekly X 2) on history of testing, symptoms, and exposure. infection or last Test 3, 6, 12 months after treatment negative test) Late latent Asymptomatic, only detected with serologic screening. Penicillin G Benzathine, 2.4 MU IM Data not clear Assess long-term sexual (> 1 year since No history of adequate treatment and last exposure/ partners/ contacts and weekly X 3 - Infectious infection) negative serology greater than 12 months ago. children as appropriate Test 12, 24 months after treatment Sexual transmission unlikely. Non-infectious, however can be transmitted transplacentally or by direct blood transfer. Non **Tertiary** Slow, progressive, inflammatory disease IV antibiotics usually (consult ID) Data not clear Assess long-term sexual (neuro, cardiovascular or gummatous syphilis), often partners/ contacts and Test 12, 24 months after treatment develops 10 to 30 years after untreated infection. children as appropriate (without CNS involvement)

For all stages:

- **Neurosyphilis** can occur during ANY stage of infection. Asymptomatic OR symptomatic (headache, visual change, hearing loss, etc.). Only clue may be a persistent elevation of NTT titres in serum despite appropriate treatment. Laboratory confirmation with a positive VDRL or syphilis PCR in CSF. Consult ID if neurosyphilis suspected.
- Test and empirically treat all partners of infectious syphilis.
- Complete and submit Provider Report Form (MHSU 6781) including contacts.
- Advise no sexual contact for 7 days after treatment is administered, until any open lesions have dried, and until partner(s) tested and treated.
- If treatment failure or reinfection is suspected, review sexual history, reassess for new or persistent signs and symptoms including CNS, consider a CSF examination, and reassess for HIV infection. If HIV testing and CSF examination is negative, treat for latent syphilis (2.4 MU IM weekly X 3) and monitor NTT.

HOW TO ASSESS FOR REINFECTION Patient with a positive syphilis serology who has previously tested positive Review details about previous positive serology including treatment and treatment response Review sexual health and immigration history 4-fold rise Consistent new Exposure(s) to infectious syphilis or higher in case(s) after their last treatment, signs and/or symptoms? the RPR? but asymptomatic and no change E.g. 1:2 → 1:8 or less than 4 fold rise in the RPR? Yes No → Yes No → Yes No Likely a new infection / New infection. Repeat testing Likely an old in 1-2 weeks re infection, especially re-infection infection not if the RPR titre are and reassess requiring at least 4 fold higher treatment Consider empiric than the last test treatment Monitor and result, e.g. 1:2 → 1:8 repeat testing

• NTT may revert to non-reactive after treatment or remain at a low steady level (e.g., ≤1:4 dilutions).

Complete staging, treatment

and follow up

- Repeat testing is not required if baseline or follow-up NTT becomes non-reactive, but may be considered in HIV-infected individuals or recent exposures to syphilis or new or persistent signs/symptoms.
- A rising NTT (4 fold or higher) after treatment may indicate treatment failure or reinfection.

as clinically

indicated

[¥] In pregnancy, if there is a delay of greater than nine days between doses, the series of injections should be restarted.

^{*} Failure of NTT titres to decrease as described may indicate treatment failure or reinfection.

[#] For exposures to a sexual partner(s) with unknown syphilis status within the previous 12 months, stage as early latent for contact tracing but treat as per late latent (X 3 weekly doses) regardless of pregnancy status.